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ABSTRACT
RT-PCR was used to diagnose dengue virus
infections conﬁrmed serologically in 26 returning
travellers. RT-PCR was positive for three (75%) of
four samples taken on or before day 3 of the
illness, for 15 (78.9%) of 19 samples taken
between days 4 and 7, and for none of three
samples tested on or after day 8 (p 0.0337). When
applied early, RT-PCR seems to be a useful tool
for the diagnosis of dengue fever.
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Dengue fever (DF) is among the most important
arthropod-borne virus diseases in terms of human
morbidity and mortality. The spectrum of this
disease, caused by the four distinct dengue virus
serotypes, DEN-1 to DEN-4, ranges from a self-
limiting febrile illness (DF) to dengue haemor-
rhagic fever ⁄dengue shock syndrome (DHF ⁄DSS)
[1]. With c. 2.5 billion people living in endemic
areas, there are 50–100 million cases of dengue
fever and 250 000–500 000 cases of DHF ⁄DS with
24 000 deaths, annually [2]. This disease has
become increasingly important in the differential
diagnosis of fever of unknown origin in returning
travellers [3–5].
Clinical observation is the key to case identiﬁ-
cation, but diagnosis by virus-speciﬁc antibody
determination is crucial for conﬁrmation and
differentiation among the different dengue virus
serotypes [1]. The existence of cross-reactive
antigenic determinants shared by all four dengue
virus serotypes and other ﬂaviviruses means that
the most precise serological diagnosis that can be
offered by many laboratories is ‘acute ﬂavivirus
infection’, rather than ‘acute dengue infection’ [1].
It has been shown that direct detection and typing
of dengue virus in serum using RT-PCR or
culturing techniques yields the most reliable
direct evidence of infection. The present study
examined the period during the course of illness
when RT-PCR could be used successfully to
detect virus in a cohort of travellers presenting
with dengue fever.
The study investigated 26 patients with sero-
logically conﬁrmed dengue fever who presented
during a 6-year period at the Department of
Infectious Diseases, Charite´ University Hospital,
Berlin, Germany. Laboratory diagnosis of dengue
fever was performed at the Robert Koch Institute,
Berlin, Germany, with virus isolation in cell
culture on the insect cell line C6 ⁄ 36, followed by
immunoﬂuorescence testing for virus antigens
with dengue virus (DEN-1, -2, -3 and -4) type-
speciﬁc monoclonal antibodies [1]. Additionally, a
ﬂavivirus type-speciﬁc RT-PCR, followed by a
semi-nested PCR with primers speciﬁc for dengue
virus strains 1–4, was performed [6]. Day 1 was
considered to be the day of onset of disease,
which is usually fever [5]. Age, gender and travel
history (i.e., dengue-endemic area visited) were
recorded for each patient. Statistical analysis was
performed with SAS v.9.1 software (SAS Institute,
Cary, NC, USA).
Of the 26 patients included in the study, 12
were female (mean age 31.3 years) and 14 were
male (mean age 35.4 years). Travel destinations
were South-east Asia (Thailand, n = 14; Indone-
sia, n = 1; Philippines, n = 1), the Indian subcon-
tinent (India, n = 4; Sri Lanka, n = 1), Central
America (El Salvador, n = 1; Nicaragua, n = 1),
South America (Venezuela ⁄Colombia, n = 1),
Paciﬁc Islands (Cook Islands, n = 1) and West
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Africa (Ghana, n = 1). Diagnosis of dengue fever
was conﬁrmed serologically by paired sera [1] in
all cases. Table 1 summarises the RT-PCR results,
grouped according to the day of illness when the
diagnostic specimen was obtained. Of 18 positive
RT-PCR results, eight were positive for DEN-1,
ﬁve for DEN-2, and ﬁve for DEN-3. Additional
virus isolation was successful and conﬁrmatory
for all eight cases positive for DEN-1, and for one
case positive for DEN-2, but for none of the cases
positive for DEN-3. Virus isolation was unsuc-
cessful for all eight serologically conﬁrmed cases
that were negative by RT-PCR. In 19 (73.1%)
cases, the initial serum sample was negative for
dengue-speciﬁc IgM antibody, but timely conﬁr-
mation of diagnosis was made by RT-PCR in 15
(78.9%) of these 19 cases.
Dengue virus infection should be considered if
the clinical signs, and geographical and epidemi-
ological circumstances, ﬁt with a possible incuba-
tion period of 5–7 days. IgM formation in primary
dengue infections usually increases markedly
around day 4 or 5 of the illness [7]. An increasing
immune response corresponds with a decreasing
virus load, and there was a statistically signiﬁcant
difference (p 0.0337) when the results of RT-PCR
were compared after < 4, 4–7 and > 7 days of
illness (Table 1).
These cases of imported dengue fever high-
light the importance of including RT-PCR in
early diagnostic procedures for travellers return-
ing from dengue endemic areas, particularly
when initial serological tests, as in the majority
of cases, show a minimal antibody response.
Direct detection and typing of dengue virus in
serum by RT-PCR is currently the fastest diag-
nostic technique for conﬁrming clinical suspi-
cion, while serotyping can provide vital
information concerning patients with secondary
dengue virus infection who are at a higher risk
of developing DHF.
Whereas the current data support the diagnos-
tic use of RT-PCR in the early phase of the
disease, the method has several limitations. Most
importantly, the period during which dengue
virus can be detected successfully in serum
samples is brief, and RT-PCR is not available in
most clinical microbiology laboratories. This
approach cannot provide live virus for further
biological characterisation, and its sensitivity
appears to vary between serotypes and protocols
[8]. However, although isolation and typing of
dengue virus might be considered to be the
reference standard, it also has a small window
of opportunity for detection [1], and modiﬁed RT-
PCR protocols have yielded better results than
virus isolation in some settings [9]. With the
possibility of using quantitative RT-PCR to
estimate the risk of an individual progressing
towards DHF, the role of this technique may
increase in the future [10]. In the meantime, as
demonstrated by molecular proﬁciency tests
[11,12], technical deﬁciencies in individual labor-
atories must be identiﬁed and eliminated. In the
future, the use of molecular techniques for the
diagnosis of imported dengue virus infections
should enable clinicians and researchers to obtain
a more precise picture of the disease’s endemicity
[13], thus facilitating a better understanding of its
epidemiology and control.
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ABSTRACT
The in-vitro and in-vivo efﬁcacy against Candida
albicans and Candida krusei of devices impregnated
with chlorhexidine and chloroxylenol was exam-
ined. The impregnated devices produced large
zones of inhibition against both organisms (mean
size, 39 mm and 38 mm, respectively). In a rabbit
model in which segments of silicone catheters
were placed percutaneously, non-impregnated
devices were twice as likely as impregnated
devices to become colonised with either C. albi-
cans or C. krusei. Impregnated devices also had
signiﬁcantly lower colony counts of C. albicans (58
vs. 1361 CFU; p 0.008) and C. krusei (19 vs.
764 CFU; p 0.008).
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Candida spp. are recognised increasingly as import-
ant causes of infection associated with medical
devices [1]. Recent surveillance data from 49
hospitals indicated that Candida spp. cause 9% of
hospital-acquired bloodstream infections [2].
Candida infections associated with medical
devices tend to be more problematic than bacterial
infections. Thus,Candida continues to be associated
with the highest crude mortality rate (39–40%)
resulting from hospital-acquired bloodstream
infections [2,3].
The serious medical complications, difﬁcult
management and high economic burden of
Candida device-associated infections prompted
an exploration of the potential preventive efﬁcacy
of innovative approaches [4]. Since device coloni-
sation can be a prelude to clinical infection [5], it
is possible that devices impregnated with agents
that possess antifungal activity may be clinically
protective. The objective of the present study was
to investigate the in-vitro and in-vivo efﬁcacy of
devices impregnated with the antiseptic combi-
nation of chlorhexidine and chloroxylenol against
Candida albicans (the most common Candida sp.)
and Candida krusei (the most inherently azole-
resistant Candida sp.).
Eighteen French silicone catheters (Cook Inc.,
Bloomington, IN, USA) were impregnated by
dipping in a solution of chlorhexidine (50 mg ⁄mL)
and chloroxylenol (50 mg ⁄mL), followed by
drying overnight and rinsing with deionised
water. Segments (2 cm) of both impregnated and
control catheters were sterilised with ethylene
oxide gas before testing. Mean quantities of
102 lg of chlorhexidine and 156 lg of chloroxyle-
nol were extracted from 2-cm segments of the
gas-sterilised impregnated catheters.
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